Denmark's ViroGates Q1 revenue rises 8%, net loss narrows

ViroGates A/S

07/05/2026 12:20

Overview

Denmark medical diagnostics firm's Q1 revenue rose 8% yr/yr to DKK 1.3 mln

Q1 net loss narrowed 6% to DKK 2.6 mln as operating expenses increased

Company filed De Novo FDA application for suPARnostic TurbiLatex after Q1 end

Outlook

ViroGates expects 2026 revenue between DKK 6 mln and DKK 7 mln

Company sees 2026 EBIT between DKK -10 mln and DKK -12 mln

Company expects further regulatory updates on suPARnostic POC+ during Q2 2026

Result Drivers

LONGEVITY SEGMENT FOCUS - Co said Q1 revenue growth was driven by increased sales in the preventive health and longevity segment

SHIFT IN CUSTOMER DEMOGRAPHICS - Recurring customer base unchanged, but more customers are from longevity accounts

Company press release: ID:nMFN3KJCyx

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Revenue
DKK 1.30 mln
Q1 Net Income
-DKK 2.60 mln
Q1 Operating Expenses
-DKK 3.85 mln
Q1 Operating Profit
-DKK 2.90 mln


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)